STO-609
CAMKK inhibitor / Selective inhibitor of Ca2+-calmodulin-dependent protein kinase kinase (Ki = 80 and 15 ng/ml for inhibition of CaM-KKα and CaM-KKβ respectively).1 Binds to the ATP-binding site.2 Displays > 80-fold selectivity over CaMK1, CaMK2, CaMK4, MLCK, PKC, PKA and p42 MAPK. Important tool for probing distinct CaMK pathways in LTP.3 Reduces starvation-induced autophagosomal membrane formation.4 Reverses age-associated decline in bone mass.5 Stimulates osteoblast formation, inhibits osteoclast differentiation.6
Biochemicals & reagents
52029-86-4
1) Tokumitsu, et al. (2002), STO-609, a Specific Inhibitor of the Ca2+/Calmodulin-dependent Protein Kinase Kinase. J. Biol. Chem. 277 15813 2) Tokumitsu, et al. (2003) A single amino acid difference between alpha and beta Ca2+/calmodulin-dependent protein kinase kinase dictates sensitivity to the specific inhibitor, STO-609.. J. Biol. Chem. 278 10908 3) Redondo, et al. (2010) Synaptic tagging and capture: differential role of distinct calcium/calmodulin kinases in protein synthesis-dependent long-term potentiation. J. Neurosci.. 30 4981 4) Pfisterer, et al. (2011) Ca+2/calmodulin –dependent kinase (CaMK) signaling via CaMKI and AMP-activated protein kinase contributes to the regulation of WIPI-1 ar the onset of autophagy Mol. Pharmacol. 80 1066 5) Pritchard et al. (2015) Inhibition of CaMKK2 reverese age-associated decline in bone mass; Bone, 75 120 6) Cary, et al. (2013) Inhibition of Ca+2/Calmodulin-dependent protein kinase kinase 2 stimulates osteoblast formation and inhibits osteoclast differentiation. J. Bone Miner. Res. 28 1599 7) 0Matsukawa et al. (2017) Upregulation of skeletal muscle PGC-1a through the elevation of cyclic AMP levels by Cyanidin-3-glucoside enhances exercise performance; Sci. Rep. 7 44799 [Focus Citation]
RT
TARGET: Kinase -- PATHWAY: Calcium signaling; Carbohydrate metabolism -- RESEARCH AREA: Stem cells; Neuroscience; Vesicles -- DISEASE AREA: Ischemia; Diabetes